Movement Alert｜HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally

Market Focus

Yesterday

On September 30, HANSOH PHARMA rose 3.16% in regular trading, trading at 34.54 HKD/share, with turnover of HKD 124 million.

On the news front, Merck and Daiichi Sankyo voluntarily withdrew their US Biologics License Application for B7-H3 ADC ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer. JP Morgan noted this development is incrementally positive for HANSOH PHARMA's competing product Ris-Rez (HS-20093) from a competitive timing perspective, maintaining an Overweight rating with a target price of HKD 50. The bank highlighted that Ris-Rez efficacy data appeared to lead I-DXd Phase II results, with a treatment-related interstitial lung disease rate of 11.7% and no Grade 4/5 events.

Additionally, HANSOH PHARMA's HS-20093 biologics license applications for both SCLC and osteosarcoma have been accepted by NMPA and included in priority review. The broader pharmaceutical sector also rallied, with CSPC Pharma up 6.17%, Hengrui Pharma up 5.83%, and China Grand Pharmaceutical up 3.87%, providing sector-wide tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1148185828"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1148185828\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1148185828?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148185828","market":"hk","top_or_hot":-1,"title":"Movement Alert｜HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally","media":"Market Focus","content":"<p><p>On September 30, HANSOH PHARMA rose 3.16% in regular trading, trading at 34.54 HKD/share, with turnover of HKD 124 million.</p><p>On the news front, Merck and Daiichi Sankyo voluntarily withdrew their US Biologics License Application for B7-H3 ADC ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer. JP Morgan noted this development is incrementally positive for HANSOH PHARMA's competing product Ris-Rez (HS-20093) from a competitive timing perspective, maintaining an Overweight rating with a target price of HKD 50. The bank highlighted that Ris-Rez efficacy data appeared to lead I-DXd Phase II results, with a treatment-related interstitial lung disease rate of 11.7% and no Grade 4/5 events.</p><p>Additionally, HANSOH PHARMA's HS-20093 biologics license applications for both SCLC and osteosarcoma have been accepted by NMPA and included in priority review. The broader pharmaceutical sector also rallied, with CSPC Pharma up 6.17%, Hengrui Pharma up 5.83%, and China Grand Pharmaceutical up 3.87%, providing sector-wide tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜HANSOH PHARMA Rises 3.16% in Regular Trading, Competitor B7-H3 ADC Withdrawal Boosts Outlook Amid Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-30 10:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 30, HANSOH PHARMA rose 3.16% in regular trading, trading at 34.54 HKD/share, with turnover of HKD 124 million.</p><p>On the news front, Merck and Daiichi Sankyo voluntarily withdrew their US Biologics License Application for B7-H3 ADC ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer. JP Morgan noted this development is incrementally positive for HANSOH PHARMA's competing product Ris-Rez (HS-20093) from a competitive timing perspective, maintaining an Overweight rating with a target price of HKD 50. The bank highlighted that Ris-Rez efficacy data appeared to lead I-DXd Phase II results, with a treatment-related interstitial lung disease rate of 11.7% and no Grade 4/5 events.</p><p>Additionally, HANSOH PHARMA's HS-20093 biologics license applications for both SCLC and osteosarcoma have been accepted by NMPA and included in priority review. The broader pharmaceutical sector also rallied, with CSPC Pharma up 6.17%, Hengrui Pharma up 5.83%, and China Grand Pharmaceutical up 3.87%, providing sector-wide tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1148185828","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148185828","pubTimestamp":1790735976,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, HANSOH PHARMA rose 3.16% in regular trading, trading at 34.54 HKD/share, with turnover of HKD 124 million.On the news front, Merck and Daiichi Sankyo voluntarily withdrew their US...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势警报|豪森制药常规交易上涨 3.16%，竞争对手 B7-H3 ADC 撤出提振行业反弹前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On September 30, HANSOH PHARMA rose 3.16% in regular trading, trading at 34.54 HKD/share, with turnover of HKD 124 million.On the news front, Merck and Daiichi Sankyo voluntarily withdrew their US Biologics License Application for B7-H3 ADC ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer. JP Morgan noted this development is incrementally positive for HANSOH PHARMA's competing product Ris-Rez (HS-20093) from a competitive timing perspective, maintaining an Overweight rating with a target price of HKD 50. The bank highlighted that Ris-Rez efficacy data appeared to lead I-DXd Phase II results, with a treatment-related interstitial lung disease rate of 11.7% and no Grade 4/5 events.Additionally, HANSOH PHARMA's HS-20093 biologics license applications for both SCLC and osteosarcoma have been accepted by NMPA and included in priority review. The broader pharmaceutical sector also rallied, with CSPC Pharma up 6.17%, Hengrui Pharma up 5.83%, and China Grand Pharmaceutical up 3.87%, providing sector-wide tailwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}